The trial to assess chelation therapy 2 (TACT2) on cardiovascular outcomes in patients with diabetes and a prior myocardial infarction (MI) was reported in September, 2024. While there was a significant reduction in circulating heavy metals following months of weekly intravenous EDTA infusions, there was not a significant reduction in cardiovascular events or mortality. You told us previously that EDTA therapy was actually beneficial, as the first TACT study showed, but that the interlopers were suppressing beneficial clinical data. Is that the reason for the failed confirmation with the TACT2 follow-up?

Unfortunately, this, indeed, is the reason for lack of efficacy in the final data analysis of this clinical study. It is flawed, and deeply so, because the interlopers want to block human use of chelation as an answer for their degradation of the human vascular system through tinkering with diet ingredients nutritionally, and the imposition of many contaminating chronic viruses that will cause pathology in the body including the vascular system. What we can tell you is that chelation is a solid choice for those who suffer from a particular configuration amenable to this strategy helping. That, you will not know without consultation with us, but it is true for a significant percentage of people. At least 25% of the population is heading down that road in having a degradation of blood flow over the years from changes that involve heavy metal deposition in the wrong places in the wrong ways, and that is potentially reversible through chelation.